Results
1 -
10 of
10Sharon M. Sagnella, Xiaojuan Gong, Minoo J. Moghaddam, Charlotte E. Conn, Kathleen Kimpton, Lynne J. Waddington, Irena Krodkiewska and Calum J. Drummond.
Nanostructured nanoparticles of self-assembled lipid pro-drugs as a route to improved chemotherapeutic agents, Nanoscale, 2011, 3, 919. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer, Cancer Chemotherapy and Pharmacology Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer, Cancer Chemotherapy and Pharmacology Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice, Journal of Cancer Research and Clinical Oncology Crystal Structure of 2u2032,3u2032-Di-O-Acetyl-5u2032-Deoxy-5-Fluorocytidine with Nu2013H??????(O,F) Proton Donor Bifurcated and (C,N)u2013H??????O Bifurcated Acceptor Dual Three-Center Hydrogen Bond Configurations, Journal of Chemical Crystallography Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients, Investigational New Drugs Simultaneous LC-MS-MS Analysis of Capecitabine and its Metabolites (5u2032-deoxy-5-fluorocytidine, 5u2032-deoxy-5-fluorouridine, 5-fluorouracil) After Off-Line SPE from Human Plasma, Chromatographia Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients, EPMA Journal Clinical Pharmacokinetics of Capecitabine, Clinical Pharmacokinetics